India's manufacturing footprint is expanding, biosimilars are gaining momentum, and FDA inspections are evolving. The latest U.S. pharmaceutical quality report offers important insights for Indian manufacturers, exporters, regulators, and pharmacy professionals.
India's Pharma Story Is Entering a New Phase
India has long been known as the "Pharmacy of the World." From supplying affordable generic medicines to over 200 countries to becoming a major manufacturer of vaccines and active pharmaceutical ingredients (APIs), the country's pharmaceutical industry has steadily strengthened its global position.
Now, the U.S. Food and Drug Administration's (FDA) FY2025 Report on the State of Pharmaceutical Quality provides fresh evidence that India's role in the global pharmaceutical supply chain continues to grow. While the report focuses on medicines supplied to the U.S. market, many of its findings have direct implications for India's pharmaceutical sector because the United States remains the largest export destination for Indian drug manufacturers.
The report tells two stories simultaneously. First, India is expanding its manufacturing presence in global pharmaceutical supply chains. Second, regulatory expectations are becoming more demanding, requiring manufacturers to demonstrate stronger quality systems, greater transparency, and continuous compliance.
For Indian pharmaceutical companies, these developments represent both an opportunity and a challenge.
Figure 1 offers one of the most compelling insights in the FDA report by illustrating how pharmaceutical manufacturing sites have shifted across major countries over the last five years. While the United States continues to dominate with 3,375 FDA-recognized manufacturing sites, its overall inventory declined by 5%, largely due to the deregistration of temporary manufacturers that entered the market during the COVID-19 Public Health Emergency, particularly alcohol-based hand sanitizer producers.
In contrast, India emerged as the fastest-growing major pharmaceutical manufacturing hub, recording a 15% increase and expanding to 606 manufacturing sites. The chart shows that India retained 469 existing facilities, added 150 new manufacturing sites, and removed only 60, resulting in the strongest net growth among all major manufacturing countries. China also strengthened its position with an 11% increase, reaching 409 sites, while Germany, Italy, Spain, and Switzerland recorded modest gains. On the other hand, Canada (-20%), the United Kingdom (-12%), and Japan (-8%) experienced noticeable declines in their manufacturing inventories.
For India, these figures represent much more than an increase in the number of factories. They reflect growing confidence among multinational pharmaceutical companies and global regulators in India's manufacturing capabilities, skilled workforce, and expanding role in supplying medicines to international markets. As one of the world's leading exporters of generic medicines and an increasingly important producer of active pharmaceutical ingredients (APIs), India's continued expansion indicates that global pharmaceutical manufacturing is gradually shifting toward Asia. At the same time, a larger manufacturing footprint also means greater regulatory responsibility. More FDA-recognized facilities translate into increased inspections, higher expectations for data integrity, stronger quality management systems, and stricter compliance with current Good Manufacturing Practices (CGMP). For Indian pharmaceutical companies, the message is clear: future growth will depend not only on expanding production capacity but also on consistently maintaining world-class quality standards that meet increasingly rigorous global regulatory expectations.
India at a Glance : Key Findings from the FDA Report
India Is Expanding Its Global Manufacturing Presence
Perhaps the most encouraging finding for India is the continued expansion of its pharmaceutical manufacturing network.
According to the FDA, India recorded one of the largest increases in manufacturing sites over the last five years, with approximately 15% growth among countries supplying medicines to the United States. Only a handful of countries showed comparable expansion.
This trend reflects more than just new factories. It indicates increasing confidence among global pharmaceutical companies in India's manufacturing capabilities, skilled workforce, and regulatory maturity.
Several factors have contributed to this growth :
• Expansion of generic medicine manufacturing
• Growing investments in biologics and biosimilars
• Government initiatives such as the Production Linked Incentive (PLI) Scheme
• Increased demand for diversified global supply chains after the COVID-19 pandemic
• Competitive manufacturing costs combined with technical expertise
For Indian pharmaceutical exporters, the FDA's data reinforces what the industry has experienced over the past decade—India is no longer viewed merely as a low-cost manufacturing destination but increasingly as a strategic partner in global medicine production.
Why This Matters
The United States imports a substantial volume of medicines manufactured in India. Every additional FDA-compliant manufacturing facility enhances India's ability to supply critical medicines to one of the world's largest pharmaceutical markets.
However, expansion also means increased regulatory scrutiny.
FDA Inspections : More Opportunity, More Responsibility
Success in the U.S. market depends not only on manufacturing capacity but also on maintaining consistently high quality standards.
The FDA carried out 1,309 inspections and inspection-equivalent evaluations during FY2025, including domestic inspections, foreign inspections, Mutual Recognition Agreement (MRA) partner inspections, and records-request reviews. India remained one of the most frequently inspected foreign manufacturing locations.
For Indian manufacturers, this carries an important message.
An FDA approval is not a one-time achievement. It is part of an ongoing quality journey that requires :
• Robust Quality Management Systems (QMS)
• Strong data integrity practices
• Effective deviation investigations
• Comprehensive documentation
• Continuous process verification
• A culture of quality across the organization
Companies that invest in these systems are likely to remain competitive in highly regulated markets.
Expert Insight
Quality is becoming a competitive advantage. In the past, companies competed primarily on manufacturing cost. Today, regulatory compliance, digital quality systems, and inspection readiness increasingly determine long-term success in global pharmaceutical markets.
India's Growing Role in API Manufacturing
While Figure 1 highlights the growth in the number of manufacturing facilities, Figure 2 provides an even more important insight—it shows how the global distribution of Active Pharmaceutical Ingredient (API) and Finished Dosage Form (FDF) manufacturing has changed over time. Rather than simply counting factories, the figure reveals where pharmaceutical production is gradually shifting within the global supply chain.
The FDA analysis shows a clear movement of manufacturing activity towards Asia. India recorded the largest increase in API manufacturing locations, rising by 3.3 percentage points, from 17.9% to 21.2% of all API manufacturing sites supporting U.S.-based applications. This represents one of the strongest gains among all regions and reinforces India's growing importance as a global supplier of pharmaceutical ingredients. At the same time, India's share of Finished Dosage Form (FDF) manufacturing also increased by 1.9 percentage points, rising from 10.5% to 12.4%. These trends indicate that India is not only producing more pharmaceutical ingredients but is also expanding its capability to manufacture finished medicines ready for patients.
China also strengthened its position, with both API and FDF manufacturing increasing by 2.5 percentage points, while Europe and the United States experienced declines across both manufacturing categories. Europe's share of API manufacturing decreased from 34.0% to 30.8%, and the United States declined from 22.9% to 21.1%. Similar reductions were observed in finished dosage form manufacturing, where the U.S. share dropped from 51.2% to 48.0%, and Europe declined from 25.1% to 24.4%. Changes in Latin America, Canada, and other regions were comparatively small, suggesting that the most significant redistribution of pharmaceutical manufacturing is occurring between traditional manufacturing hubs and emerging Asian producers.
For India, these numbers carry strategic significance. APIs are the backbone of every medicine, while FDF manufacturing represents the final stage that delivers tablets, capsules, injections, and other dosage forms to healthcare systems worldwide. Growth in both segments demonstrates that India is steadily moving up the pharmaceutical value chain rather than remaining only a supplier of low-cost generic medicines. This evolution supports the country's ambition to become a comprehensive global manufacturing hub capable of producing everything from pharmaceutical ingredients to complex finished formulations.
Biosimilars Could Be India's Next Growth Engine
Another major trend highlighted in the FDA report is the continued rise of biological medicines. Although biologics still represent a relatively small proportion of total FDA approvals, their importance is increasing rapidly. Biosimilars now account for a significant share of newly approved biologics, reflecting the maturation of this market.
For India, this presents a major opportunity. Indian companies have already established capabilities in vaccines, recombinant proteins, and monoclonal antibodies. As more biologic products lose patent protection worldwide, demand for affordable biosimilars is expected to grow, opening new export opportunities for Indian manufacturers that can meet stringent international quality standards.
What Indian Pharmacy Students Should Learn from This Report
The FDA report is not only relevant for pharmaceutical companies. It also offers valuable lessons for students and young professionals.
Tomorrow's pharmaceutical workforce will require expertise beyond traditional manufacturing. Careers are increasingly expanding into:
• Quality Assurance
• Regulatory Affairs
• Data Integrity
• Pharmaceutical Quality Systems
• Process Validation
• Risk Management
• Global Regulatory Compliance
Pharmaceutical Data Analytics
Understanding international regulatory expectations will become an essential skill for pharmacists working in manufacturing, clinical research, and regulatory sciences.
Looking Ahead
The FDA's FY2025 report makes one point abundantly clear: pharmaceutical quality is becoming increasingly data-driven, globally interconnected, and risk-based.
For India, this evolution creates significant opportunities—but only for manufacturers prepared to invest in world-class quality systems, advanced manufacturing technologies, and continuous regulatory compliance.
The country's growing manufacturing footprint demonstrates international confidence in Indian pharmaceutical capabilities. Maintaining that confidence will require innovation, transparency, and an unwavering commitment to quality.
As India's pharmaceutical industry continues its transformation from a global supplier of affordable medicines to a leader in advanced pharmaceutical manufacturing, quality will remain the foundation on which future success is built.
The FDA report is therefore more than an annual regulatory publication—it is a roadmap highlighting where global pharmaceutical manufacturing is headed and how India can continue strengthening its position within it.
By PharmaTutor Editorial Team
